Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Clinical trial NCT04862286 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04862286
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-24
- Primary completion
- 2028-04-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.